Human embryonic stem cell-derived cardiomyocytes for drug safety testing



July 18, 2012

  • Share
  • View compelling data that shows how human embryonic stem cell derived Cytiva™ cardiomyocytes can be a powerful approach to assessing cardiac drug liabilities. Nick Thomas, Principal Scientist at GE Healthcare Life Sciences describes how hESC derived Cytiva cardiomyocytes: •are a valid model of cardiomyocytes from the human heart •are compatible with assays routinely used for testing cardiotoxicity •together with high-content assays and analysis, can indicate the mechanism of toxicity of drug compounds.

    BioengineeringDrug DiscoveryGenomicsStem Cells

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.